Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: Relationship with metabolic bone disease

Liver International

Volumn 27, Issue 4, 2007, Pages 492-497

  Monegal, Ana ^a,b   Navasa, Miquel ^a   Peris, Pilar ^a   Alvarez, Luisa ^a   Pons, Francesca ^a   Rodés, Joan ^a   Guañabens, Nuria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Bone markers; Liver disease; Osteoporosis; Osteoprotegerin; RANKL

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE TURNOVER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FEMUR NECK; FRACTURE; HIP; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METABOLIC BONE DISEASE; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT REFERRAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; FRACTURES, BONE; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OSTEOPOROSIS; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RANK LIGAND;

EID: 34047203809     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01448.x     Document Type: Article

References (18)

1. Guañabens N, Monegal A. Bone disease after liver transplantation. In: Compston J, Shane E, eds. Bone Disease of Organ Transplantation. London: Elsevier Academic Press, 2005; 271-85.
2. Monegal A, Navasa M, Guañabens N, et al. Bone disease after liver transplantation. A long term prospective study of bone mass changes, hormonal disorders and histomorphometric characteristics. Osteoporos Int 2001; 12: 484-92.
3. Monegal A, Navasa M, Guañabens N, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 148-54.
4. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
5. Simonet WS, Lacey DL, Dunstan CR, et el. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
6. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappa β ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-53.
7. Szalay F, Hegedus D, Lakatos PL, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003; 38: 395-400.
8. Gonzalez-Calvin JL, Mundi JL, Casdo FJ, Olivares EG. Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis. Gastrenterology 2004; 126: 1225-6.
9. Fábrega E, Orive A, García-Suarez C, et al. Osteoprotegerin and RANKL in alcoholic liver cirrosis. Liver Int 2005; 25: 305-10.
10. Moschen AR, Kaser A, Stadlmann S, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005; 43: 973-83.
11. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santolaria-Fernandez F, et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol 2006; 3: 261-6.
12. Fahrleitner A, Prenner G, Leb G, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003; 32: 96-106.
13. Wiesner R, Edwards E, Freeman R, et al. Model for End-stage Liver Disease (MELD) and allocation of donors livers. Gastroenterology 2003; 124: 91-6.
14. Guañabens N, Parés A, Alvarez L, et al. Collagen related markers of bone turnover reflect the severity of liver fibrosis in patients with billiary primary cirrhosis. J Bone Miner Res 1998; 13: 731-8.
15. Khosla S, Arrighi HM, Melton LJ III, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002; 13: 394-9.
16. Mezquita-Raya P, de la Higuera M, Fernandez Garcia D, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005; 16: 1368-74.
17. Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004; 291: 1108-13.
18. Enjuanes A, Guañabens N, Alvarez L, et al. Osteoprotegerin gene expressión in the liver of patients with primary biliary cirrhosis. Lack of association with elevated circulating levels. J Bone Miner Res 2005; 20 (Suppl. 1): S167.